TABLE III.
Grade 3 or greater adverse effects of first-line chemotherapy
| Variable | Chemotherapy group [n (%)] | ||
|---|---|---|---|
|
| |||
| Irinotecan doublet | Oxaliplatin doublet | Capecitabine | |
| Patients | 28 | 14 | 38 |
| Dose reductiona | 10 (36) | 10 (71) | 5 (13) |
| Neutropenia | 10 (40) | 0 (0) | 0 (0) |
| Thrombocytopenia | 0 (0) | 0 (0) | 0 (0) |
| Anemia | 0 (0) | 0 (0) | 0 (0) |
| Hand–foot syndrome | 1 (4) | 2 (14) | 5 (13) |
| Peripheral neuropathy | 1 (4) | 4 (29) | 0 (0) |
| Diarrhea | 2 (7) | 0 (0) | 1 (3) |
| Febrile neutropenia | 2 (7) | 0 (0) | 0 (0) |
| Hospital admissionb | 3 (11) | 1 (7) | 4 (11) |
a
Includes all dose reductions that occurred after cycle 1 of chemotherapy.
b
Because of infectious complications.